Vericel Corporation (VCEL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.68 (+2.98%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Vericel Corporation (VCEL)
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $57.67
  • Market Cap

    $2.85 Billion
  • Total Outstanding Shares

    49.36 Million Shares
  • Total Employees

    314
  • Dividend

    No dividend
  • IPO Date

    February 4, 1997
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.vcel.com

Historical Stock Splits

If you bought 1 share of VCEL before October 16, 2013, you'd have 0.05 shares today.
Execution DateSplit Amount
October 16, 20131-for-20 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$46.01 Million
Net Cash Flow From Financing Activities$13.25 Million
Net Cash Flow From Investing Activities$-72.47 Million
Net Cash Flow From Operating Activities$46.01 Million
Net Cash Flow From Financing Activities, Continuing$13.25 Million
Net Cash Flow From Investing Activities, Continuing$-72.47 Million
Net Cash Flow$-13.21 Million
Net Cash Flow, Continuing$-13.21 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss$3.55 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Revenues$226.84 Million
Cost Of Revenue$64.73 Million
Net Income/Loss Available To Common Stockholders, Basic$3.55 Million
Costs And Expenses$222.20 Million
Research and Development$24.77 Million
Income/Loss From Continuing Operations Before Tax$4.65 Million
Net Income/Loss Attributable To Parent$3.55 Million
Diluted Average Shares$48.69 Million
Preferred Stock Dividends And Other Adjustments$0.00
Benefits Costs and Expenses$222.20 Million
Operating Expenses$163.34 Million
Basic Average Shares$48.69 Million
Basic Earnings Per Share$0.08
Diluted Earnings Per Share$0.08
Income/Loss From Continuing Operations After Tax$3.55 Million
Nonoperating Income/Loss$5.88 Million
Operating Income/Loss$-1.23 Million
Income Tax Expense/Benefit$1.10 Million
Gross Profit$162.12 Million
Selling, General, and Administrative Expenses$138.57 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Liabilities And Equity$390.40 Million
Liabilities$132.93 Million
Wages$3.09 Million
Equity$257.47 Million
Other Current Assets$174.76 Million
Assets$390.40 Million
Inventory$15.76 Million
Accounts Payable$20.88 Million
Current Liabilities$41.35 Million
Current Assets$190.52 Million
Other Current Liabilities$17.38 Million
Noncurrent Liabilities$91.59 Million
Noncurrent Assets$199.88 Million
Equity Attributable To Parent$257.47 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.